Favorable interaction of β-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus

Biochemical Pharmacology

Volumn 51, Issue 6, 1996, Pages 731-736

  Bridges, Edward G ^a   Dutschman, Ginger E ^a   Gullen, Elizabeth A ^a   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anti HIV nucleoside; mitochondrial DNA; synergy

Indexed keywords

2',3' DIDEOXY 5 FLUOROCYTIDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; MITOCHONDRIAL DNA; NUCLEOSIDE DERIVATIVE; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MITOCHONDRION; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0029965190     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00056-1     Document Type: Article

References (17)

1. Shirasaka T, Yarchoan R, O'Brien MC, Husson RN, Anderson BD, Kojima E, Shimada T, Broder S and Mitsuya H, Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: An in vitro comparative study. Proc Natl Acad Sci USA 90: 562-566, 1993.
2. Boucher CAB, Tersmette M, Lange JMA, Kellam P, de Goede REY, Mulder JW, Darby G, Goudsmit J and Larder BA, Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet 336: 585-590, 1990.
3. Dornsife RE, St. Clair MH, Huang AT, Panella TJ, Koszalka GW, Burns CL and Averett DR, Anti-human immunodeficiency virus synergism by zidovudine (3′-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob Agents Chemother 35: 322-328, 1991.
4. Eron JJ Jr, Johnson VA, Merrill DP, Chou TC and Hirsch MS, Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2′,3′-dideoxycytidine in vitro. Antimicrob Agents Chemother 36: 1559-1562, 1992.
5. Cox S, Metabolism of 3′-azido-3′-deoxythymidine and 3′-fluoro-3′-deoxythymidine in combination in human immunodeficiency virus infected lymphoblastoid cells. Antiviral Chem Chemother 3: 165-170, 1992.
6. Meng TC, Fischl MA, Boota AM, Spector SA, Bennet D, Bassiakos T, Lai SH, Wright B and Richman DD, Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med 116: 13-20, 1992.
7. Coats JAV, Cammack N, Jenkinson HJ, Mutton IM, Pearson BA, Storer R, Cameron JM and Penn CR, The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH-189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother 36: 202-205, 1992.
8. Schinazi RF, McMillan A, Cannon D, Mathis R, Lloyd RM, Peck A, Sommadossi JP, St. Clair M, Wilson J, Furman PA, Painter G, Choi WB and Liotta DC, Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-cytosine. Antimicrob Agents Chemother 36: 2423-2431, 1992.
9. Lin TS, Luo MZ, Liu MC, Pai SB, Dutschman GE and Cheng YC, Antiviral activity of 2′,3′-dideoxy-β-L-5-fluorocytidine (β-L-FddC) and 2′,3′-dideoxy-β-L-cytidine (β-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochem Pharmacol 47: 171-174, 1994.
10. Mellors JW, Dutschman GE, Im GJ, Tramontano E, Winkler SR and Cheng YC, In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol Pharmacol 41: 446-451, 1992.
11. Larder BA, Chesebro B and Richman DD, Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother 34: 436-441, 1990.
12. Parker WB, Shaddix SC, Bowdon BJ, Rose LM, Vince R, Shannon WM and Bennet LL Jr, Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects on cellular metabolism. Antimicrob Agents Chemother 37: 1004-1009, 1993.
13. White EL, Parker WB, Ross LJ and Shannon WM, Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5′-triphosphates of various anti-HIV nucleoside analogues. Antiviral Res 22: 295-308, 1993.
14. Larder BA, Kemp SD and Harrigan PR, Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269: 696-699, 1995.
15. Parker WB and Cheng YC, Mitochondrial toxicity of antiviral nucleoside analogs. J NIH Res 6: 57-61, 1994.
16. Faraj A, Agrofoglio LA, Wakefield JK, McPherson S, Morrow CD, Gosselin G, Mathes C, Imbach J-L, Schinazi RF and Sommadossi J-P, Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5′-triphosphate β enantiomers of cytidine analogs. Antimicrob Agents Chemother 38: 2300-2305, 1994.
17. Schinazi RF, Lloyd RR Jr, Nguyen M-H, Cannon DL, McMillan A, Ilksoy N, Chu CK, Liotta DC, Bazmi HZ and Mellors JW, Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 38: 875-881, 1993.